NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01643603 2020-12-17Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesBarbara Ann Karmanos Cancer InstitutePhase 1 Terminated5 enrolled
NCT00036738 2020-01-29Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibFred Hutchinson Cancer CenterPhase 2 Completed28 enrolled 10 charts
NCT00316953 2013-02-05Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateNational Cancer Institute (NCI)Phase 1 Completed48 enrolled
NCT00345826 2013-01-08Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaJonsson Comprehensive Cancer CenterPhase 1 Completed19 enrolled
NCT00101816 2010-08-10Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateBristol-Myers SquibbPhase 2 Completed124 enrolled 28 charts